title: Hepatitis C Treatment: Clinical Issues for Psychiatrists in the Post-Interferon Era.
abstract: Hepatitis C virus (HCV) is a widespread and costly cause of morbidity and mortality globally and in the United States. The treatment of HCV has been revolutionized with the recent development of direct-acting antiviral medications. These new treatments are substantially better tolerated and more efficacious than previously used interferon-based therapies. Despite these innovations, sustained virologic response has remained low, hovering at approximately 9% of all infected persons. The reasons for this failure include lack of screening, low rates of linkage to care, cost of direct-acting antivirals, and barriers in access to care for patients. Psychiatrists work with patients at a disproportionately high risk for HCV infection yet many do not currently assume an active role in the HCV epidemic.
  
  
  
  The purpose of this clinical review is to familiarize psychiatrists with currently available hepatitis C treatments and discuss the remaining treatment challenges, including the high cost of treatment.
  
  
  
  The authors used information from the Centers for Disease Control and Food and Drug Administration on the most current estimates of HCV epidemiology, risk factors, and approved interferon-free treatments. PUBMED was searched for examples of HCV treatment in community psychiatry settings.
  
  
  
  The mental health community is well-positioned to take on a more active role in HCV treatment and engage patients׳ trust in the treatment process. However, many barriers still exist. We encourage psychiatrists to assume a collaborative role in caring for psychiatric patients infected with HCV.
authors.affiliation: MGH-McLean Adult Psychiatry Residency Training Program, Massachusetts General Hospital, Boston, MA; Harvard Medical School, Boston, MA. Electronic address: ychasser@partners.org.
authors.forename: Yvonne
authors.initials: Y
authors.lastname: Chasser
authors.affiliation: Division of Infectious Diseases, Department of Child Psychiatry, Massachusetts General Hospital, Boston, MA; Harvard Medical School, Boston, MA.
authors.forename: Arthur Y
authors.initials: AY
authors.lastname: Kim
authors.affiliation: Schizophrenia Clinical and Research Program, Massachusetts General Hospital, Boston, MA; Harvard Medical School, Boston, MA.
authors.forename: Oliver
authors.initials: O
authors.lastname: Freudenreich
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D003299:Cooperative Behavior; D006297:Health Services Accessibility; D006526:Hepatitis C / Q000150:complications* / Q000188:drug therapy*; D006801:Humans; D001523:Mental Disorders / Q000150:complications* / Q000628:therapy; D024382:Professional Role; D011570:Psychiatry
chemical_list: D000998:Antiviral Agents
keywords: barriers to care; epidemiology; hepatitis C; integrated care; schizophrenia; serious mental illness